Statin Therapy Guidelines

Indications and Contraindications

• Statins may be used to reduce LDL-cholesterol and prevent cardiovascular risk, with no benefits or harm on liver disease, as stated by the European Association for the Study of the Liver (EASL) guidelines 1
• The American College of Cardiology recommends considering statin therapy based on overall cardiovascular risk profile, not solely on LDL level, for patients with clinical ASCVD, LDL-C ≥190 mg/dL, diabetic patients aged 40-75 with elevated ASCVD risk, and primary prevention patients with 10-year ASCVD risk ≥7.5% 1, 2
• Baseline measurement of transaminase (ALT) levels should be performed before initiation of statin therapy and measured during therapy only if symptoms suggestive of hepatotoxicity develop, as recommended by the American College of Cardiology 3
• LDL-C should be checked 4-12 weeks after initiating therapy to assess response, as recommended by the American College of Cardiology 3, 2

Risk Assessment and Monitoring

• Myopathy risk factors include age >75 years, multiple comorbidities, impaired renal/hepatic function, and concomitant medications affecting statin metabolism, as suggested by the American College of Cardiology 4, 5
• Statins modestly increase risk for developing type 2 diabetes, but cardiovascular benefits outweigh this risk, as stated by the American College of Cardiology 3
• Muscle symptoms occur in 5-10% of patients, and risk factors for myopathy include age >75 years, multiple comorbidities, impaired renal/hepatic function, history of muscle disorders, and concomitant medications affecting statin metabolism 5
• Simvastatin 80 mg should be avoided due to increased risk of myopathy 2
• Drug interactions, particularly with medications metabolized by CYP3A4, should be considered 5

Special Considerations

• The European Association for the Study of the Liver (EASL) guidelines do not support the use of statins for improving non-alcoholic fatty liver disease (NAFLD) as a primary outcome 1
• There is no evidence supporting statin use for weight loss, and weight management should be addressed through lifestyle modifications including diet and physical activity 1
• Statin therapy is recommended for patients with clinical ASCVD (secondary prevention) under age 75, patients with LDL-C ≥190 mg/dL, diabetic patients aged 40-75 with high ASCVD risk, and primary prevention patients with 10-year ASCVD risk ≥7.5%, as recommended by the American Heart Association and American College of Cardiology 2
• Statin therapy is also recommended for ASCVD patients over age 75, diabetic patients aged 40-75 with lower ASCVD risk, and primary prevention patients with 10-year ASCVD risk of 5-7.5%, as recommended by the American Heart Association and American College of Cardiology 2
• Statins are categorized by intensity, with high-intensity statins including atorvastatin 40-80 mg and rosuvastatin 20-40 mg, and moderate-intensity statins including atorvastatin 10-20 mg and rosuvastatin 5-10 mg 2
• Moderate-intensity statin therapy is generally preferred over high-intensity due to safety concerns, but clinical judgment should guide therapy decisions, considering comorbidities and potential drug interactions 2
• High-intensity statin therapy should be initiated as early as possible during hospitalization, with a target LDL-C reduction of ≥50% from baseline 5, 6
• Pravastatin, atorvastatin, and fluvastatin have been studied in HIV-infected patients on protease inhibitors, and potential drug interactions with antiretroviral therapy should be considered 7

Potential Pitfalls

• Failure to assess cardiovascular risk before selecting statin intensity can lead to inappropriate therapy decisions, and risk calculators should be used to guide therapy decisions 3
• Inappropriate dose adjustments based solely on achieved LDL-C levels can lead to inadequate therapy, and the 2013 ACC/AHA guideline recommends treating to appropriate intensity statin therapy based on risk 3
• Discontinuing statins due to mild muscle symptoms without proper evaluation can lead to unnecessary discontinuation of therapy, and true statin-related myopathy is rare 5
• Overlooking drug interactions can lead to increased risk of adverse effects, and medications that may increase statin concentrations should be carefully monitored 5